Tumor Multiplicity Is an Independent Prognostic Factor of Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy
Ajili F, Manai M, Darouiche A, Chebil M, Boubaker S. Ultrastruct Pathol. 2012 Oct;36(5):320-4. doi: 10.3109/01913123.2012.681833.

Source

Laboratory of Human and Experimental Pathology, Pasteur Institute of Tunis, Tunisia, and Laboratory of Biochemistry and Molecular Biology, University of Science , Tunis , Tunisia.

Abstract

Background: Bacillus Calmette-Guerin (BCG) immunotherapy is regarded as the current treatment of choice for non muscle invasive bladder cancer (NMIBC), though its efficacy is limited by high recurrence and progression rate. Identification of factor prognosticators that might be helpful in discriminating between responders and nonresponders to BCG treatment is therefore of major clinical importance. The aim of this study is to evaluate the prognostic factors of recurrence after intravesical adjuvant BCG immunotherapy in patients with NMIBC. Methods: we retrospectively reviewed the clinical and pathologic data of primary NMIBC from 112 patients who were treated with transurethral resection followed by BCG-immunotherapy. Time follow-up was 30 months. The prognostic significance of tumor stage, grade, multiplicity, age, sex and smoking in determining the risk for recurrence after BCG therapy was studied with both univariate and multivariate methods of analysis. Results: According to univariate analysis of the prognostic significance for tumor stage, grade, loci number, sex, age and smoking, the pT1 stage and multiplicity seem to be associated in a statistically significant manner with higher risk for recurrence (P = 0.009, P = 0.011, respectively). In the other hand, multivariate analysis showed that only multiplicity was an independent significant prognosticator. Conclusion: Significant independent predictor for recurrence was multiplicity which offers important clinical information and may be a useful tool in the selection of suitable candidates for BCG-immunotherapy.